Just saw this in a Forbes news flash this morning.
'In other news, Germany's Merck says it will file with European regulators to market cancer drug
Erbitux to treat head and neck cancer at the start of 2005. Merck, which licenses rights to sell the drug in certain markets from its creator ImClone Systems (nasdaq: IMCL - news - people ), says its sales of
Erbitux could bring in $608 million in peak annual sales by 2008.'
Not that we care about the money part, but I think this means it may soon be available to us H & N patients in this country. That's the route it took to get approval for colorectal cancers.
Just thought it interesting.
Eileen